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1015-9584/Copyright ª 2014, Asian SuSummary Objective: To compare the survival outcome of various treatment modalities for
organ-confined muscle-invasive urothelial carcinoma of the bladder.
Methods: One hundred and fifty patients with Stage II (T2, N0, M0) or Stage III (T3a-T4a, N0,
M0) urothelial carcinoma of the bladder treated at the National Referral Hospital and the Na-
tional Cancer Center of Indonesia from 1995 to 2010 with a minimum follow-up period of 24
months were included in this study. Overall survival and mean survival times were analyzed us-
ing the KaplaneMeier method.
Results: The mean  standard deviation age of the patients in this study was 57.15  11.6
years and 88% were men. Over 50% of patients had T2 disease, 24.2% had T3 disease, and
21.5% had T4 disease based on pathology. Based on histological grade, 30.8% were intermedi-
ate grade tumors and 42.1% were high-grade tumors. Radical cystectomy was performed in 20
patients (13.3%) and 40 patients (26.7%) were treated with radiotherapy. Ninety (60%) patients
underwent transurethral resection of the bladder tumor only without further definitive treat-
ment for personal reasons. The actuarial 5-year overall survival for all patients was as follows:
radical cystectomy, 50%; radiotherapy, 22.7%; and transurethral resection of the bladder tu-
mor only, 8.3% (log-rank p Z 0.029). For stage T2 patients, the 5-year overall survival was:
radical cystectomy, 62.5%; radiotherapy, 31.2%; and transurethral resection of the bladder tu-
mor only, 8.3% (log-rank p Z 0.017).eclare that they have no financial or non-financial conflicts of interest related to the subject matter
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Treatment outcomes for invasive bladder cancer 185Conclusion: In our series, radical cystectomy had a superior outcome to radiotherapy or trans-
urethral resection of the bladder tumor only, comparable with results reported elsewhere.
Radical cystectomy should be offered as the gold standard treatment for organ-confined mus-
cle-invasive urothelial carcinoma of the bladder.
Copyright ª 2014, Asian Surgical Association. Published by Elsevier Taiwan LLC. All rights
reserved.1. Introduction
Bladder cancer is one of themost commonprimary cancers in
men in Indonesia, possibly linked to the high prevalence of
smoking. Indonesia as a country is the third largest consumer
of cigarettes in the world.1 Urothelial carcinoma of the
bladder accounts for 80% of all bladder cancers in Indonesia.2
The majority of cases of urothelial carcinoma of the bladder
in Indonesia are muscle-invasive bladder cancer (MIBC)
confined to the organ, with localized Stage IIeIII diseasewith
no lymph node involvement or distant metastasis.3
Curative treatment options for organ-confined invasive
urothelial carcinoma of the bladder include radical cys-
tectomy or external beam radiotherapy, preferably with
neoadjuvant or adjuvant chemotherapy.4,5 Although the
most important consideration in the choice of treatment
should be oncological cure, the role of these primary
treatment modalities remains the subject of ongoing
debate due to the absence of a clear-cut superiority of
either treatment in terms of mortality, morbidity, and
subsequent quality of life. It is understandable that there
are variations in treatment policies in different regions and
hospitals in the choice of primary treatment for MIBC.6e8
There are currently no published data on the treatment
outcomes of organ-confined MIBC in Indonesia. This study
aimed to compare the overall survival between various
treatment modalities for organ-confined MIBC in Indonesian
patients by extrapolating retrospective data from two ter-
tiary referral hospitals in Jakarta, Indonesia.
2. Methods
One hundred and fifty patients diagnosed with Stage II (T2a-
T2b, N0, M0) or Stage III (T3a-T4a, N0, M0) urothelial carci-
noma of the bladder and treated at the Cipto Mangunkusomo
National Referral Hospital and Dharmais National Cancer
Center, Jakarta, Indonesia between January 1995 and
December 2010 were included. Survival analysis was per-
formed on all patients with urothelial carcinoma of the
bladder with a minimum follow-up period of 24 months. In-
dividual patient data were collected using a standardized
medical form and a database was compiled. The data
included the patient’s age, sex, tumor type, pathological
stage, tumor grade, treatment, and status at follow up.
The treatment guidelines for MIBC in Indonesia follow
the European Association of Urology and the National
Comprehensive Cancer Network guidelines on the treat-
ment of bladder cancer.4,5 Diagnosis of the bladder tumor
type was determined by histopathological examination of
tissue samples from transurethral resection of the bladder
tumor or a bladder biopsy sample in patients with asuspected urothelial carcinoma. Bladder tumors were
graded histologically according to World Health Organiza-
tion/International Society of Urological Pathology
consensus classification of urothelial carcinoma of the
bladder.9
The pathological stage was classified by the TNM system.
Tumor (T) staging was determined by performing bimanual
palpation before and after transurethral resection of the
bladder tumor, evaluating the depth of tumor penetration
on histology, or from the results of radical cystectomy.
Nodal (N) staging was determined by computed tomography
scan or lymph node dissection. Evaluation for distant
metastasis (M) included chest radiographs, abdomi-
nalepelvic ultrasonography and computed tomography. A
radioisotope bone scan was performed in advanced stage
tumors with a suspicion of bone metastasis.
Radical cystectomy with appropriate lymph node
dissection is the preferred treatment for patients with
Stage IIeIII muscle-invasive urothelial carcinoma of the
bladder. Radical cystectomy includes the removal of the
bladder, prostate, and seminal vesicles in male patients
and the uterus and the ovaries in female patients. Bilateral
pelvic lymphadenectomy included removal of the obturator
lymph nodes, external iliac, and internal iliac, to the extent
of mid-common iliac vessels as the proximal limit. Urinary
diversion was performed with either ileal conduit, neo-
bladder, or percutaneous nephrostomy. The choice of uri-
nary diversion was determined with consideration of the
patients’ condition and the preference of the surgeon. The
most common urinary diversion performed in our patients
was ileal conduit; the detailed operative techniques and
outcomes have been described previously.10
External beam radiotherapy is a primary treatment
alternative for patients who refuse surgery or for those
unsuitable for surgery due to age or other comorbidities.
Neoadjuvant or adjuvant treatments were not given to
patients in this study. The total radiation dose delivered to
the whole pelvis and lymph nodes was in the range
40e50 Gy, followed by a booster to the bladder tumor,
giving a total radiation dose of 66 Gy. After the completion
of radiotherapy, patients were reassessed with cystoscopy
and examination under anesthesia; further bladder biopsies
were performed to investigate patients who did not have a
complete clinical response. Patients who had an abnor-
mality on cystoscopy, but had a negative biopsy sample,
were considered to have had a complete clinical response.
The primary outcome was the overall survival of each
treatment group. Overall survival was defined from the
date of pathological diagnosis to mortality from any cause.
KaplaneMeier survival analysis was used to calculate the 5-
year overall survival rate and the mean survival time. A log-
rank (ManteleCox) test was used for survival comparisons
Table 2 Characteristics of the active treatment groups.
Characteristic Radical Radiotherapy p
186 W. Supit et al.between treatments. Data were analyzed using SPSS soft-
ware (version 16; SPSS, Chicago, IL, USA); p  0.05 was
considered statistically significant.cystectomy
group
group
Age (y) 51.05  8.22 62.87  13.17 0.01
pT
2a 9 (45.0) 22 (55.0) 0.106
2b 2 (10.0) 0 (0)
3a 5 (25.0) 7 (17.5)
3b 2 (10.0) 1 (2.5)
4a 2 (10.0) 10 (25.0)
Grade
1 4 (23.5) 3 (7.9) 0.156
2 4 (23.5) 17 (44.7)
3 9 (52.9) 18 (47.4)
Stage
II 11 (55.0) 22 (55.0) 0.607
III 9 (45.0) 18 (45.0)
Karnofsky score (%)
100 2 (11.1) 6 (15.4) 0.203
80e90 12 (66.7) 29 (74.4)
60e70 2 (11.1) 4 (10.3)
50 2 (11.1) 0 (0)
Mean delay (d) 29.88  36.72 84.95  156.78 0.161
Data are presented as mean  SD or n (%).3. Results
The mean  standard deviation age was 57.15  11.6 years
and 88% of the patients were men. Based on pathological
stage, over 50% of the tumors were T2, followed by T3
(24.2%), and T4 (21.5%). Based on histological grade, 12
tumors (9%) were low grade, 41 (30.8%) were intermediate
grade, and 107 (42.1%) were high grade. Active treatments
included radical cystectomy in 20 patients (13.3%) and
radiotherapy in 40 patients (26.7%). The remaining 90 pa-
tients (60%) underwent transurethral resection of the
bladder tumor only and refused further treatment
(Table 1).
Between the active treatment groups (radical cys-
tectomy vs. radiotherapy), the baseline characteristics
including pathologic T (pT), grade, stage, and Karnofsky
performance score were similar. There was a statistically
significant difference in the mean age of the radical cys-
tectomy group (51.1 years) compared with the radiotherapy
group (62.9 years); pZ 0.01. The mean delay to treatment
in the radiotherapy group (85 days) was also longer than in
the radical cystectomy group (30 days), although the dif-
ference was statistically insignificant (Table 2).
The KaplaneMeier survival analyzes for all patients are
summarized in Table 3 and Fig. 1. The 5-year overall sur-
vival for all patients in each treatment group was 50% in the
radical cystectomy group, 22.7% in the radiotherapy group,
and 8.3% in the transurethral resection of the bladderTable 1 Patients’ characteristics.
Characteristic
Age (y) 57.15  11.6
(30e85)
Sex
Male 132 (88.0)
Female 18 (12.0)
pT
2a 75 (50.3)
2b 6 (4.0)
3a 32 (21.5)
3b 4 (2.7)
4a 32 (21.5)
Grade
1 12 (9.0)
2 41 (30.8)
3 80 (60.2)
Stage
II 82 (54.7)
III 68 (45.3)
Treatment
Radical cystectomy 20 (13.3)
Radiotherapy 40 (26.7)
Transurethral resection
of the bladder tumor only
90 (60.0)
Data are presented as mean  SD (range) or n (%).tumor only group. The mean survival time was 62.3 months,
42.44 months, and 25.7 months in each treatment group,
respectively. For all patients, the pair-wise overall survival
log-rank comparisons were radical cystectomy versus
transurethral resection of the bladder tumor only
(pZ 0.031), radiotherapy versus transurethral resection of
the bladder tumor only (p Z 0.046), radical cystectomy
versus radiotherapy (p Z 0.44), and overall survival com-
parisons (log-rank p Z 0.029).
When patients treated with radiotherapy and transure-
thral resection of the bladder tumor only were combined as
a group, the KaplaneMeier estimated mean survival time
was 36.1 months with a 5-year overall survival of 15.2%. The
overall log-rank comparisons between this treatment group
and the radical cystectomy group was p Z 0.118.
Survival outcomes of stage T2 patients are summarized
in Table 4 and Fig. 2. The 5-year overall survival for T2
patients in each treatment group was 62.5% in the radical
cystectomy group, 31.2% in the radiotherapy group, and
8.3% in the transurethral resection of the bladder tumor
only group. The mean survival times were 89.85 months,
52.98 months, and 14.83 months in each treatment group,
respectively. For stage T2 patients, the pair-wise overallTable 3 Five-year overall survival of all patients.
Treatment 5-y overall
survival (%)
Mean survival
time (mo)
Radical cystectomy 50.0 62.32
Radiotherapy 22.7 42.44
Transurethral resection of
the bladder tumor only
8.3 25.71
KaplaneMeier log-rank (ManteleCox) p Z 0.029.
Figure 1 Five-year overall survival of all patients.
TUR-BT Z transurethral resection of the bladder tumor.
Figure 2 Five-year overall survival of stage T2 patients.
TUR-BT Z transurethral resection of the bladder tumor.
Treatment outcomes for invasive bladder cancer 187survival log-rank comparisons were radical cystectomy
versus transurethral resection of the bladder tumor only
(pZ 0.035), radiotherapy versus transurethral resection of
the bladder tumor only (p Z 0.017), radical cystectomy
versus radiotherapy (p Z 0.355), and overall survival
comparisons (log-rank p Z 0.017).
4. Discussion
MIBC has a wide range of presentations and the optimum
treatment strategy depends on the stage and grade of
disease. The selection of treatment should be focused on
the goal of achieving an optimum oncological outcome
while maintaining the patient’s quality of life. According to
clinical practice guidelines, radical cystectomy with bilat-
eral pelvic lymphadenectomy is considered the standard
treatment for patients with localized muscle-invasive uro-
thelial carcinoma. However, bladder-preserving ap-
proaches to further improve their quality of life may be
considered in selected patients. Patients with smaller iso-
lated tumors may be particularly suitable for an organ-
conserving approach including external-beam radiotherapy
with neoadjuvant or adjuvant chemotherapy.4,5
Invasive bladder urothelial carcinoma is very aggressive
and is known to have a poor prognosis, with fewer than 15%
of patients surviving 2 years if untreated.11 Based on pub-
lished evidence, patients in our centers were offered a
primary choice of cystectomy or radiotherapy (for older
patients with comorbidities or those who refused surgery
for personal reasons). Half of our patients declined furtherTable 4 Five-year overall survival of stage T2 patients.
Treatment 5-y overall
survival (%)
Mean survival
time (mo)
Radical cystectomy 62.5 89.85
Radiotherapy 31.2 52.98
Transurethral resection of
the bladder tumor only
8.3 14.83
KaplaneMeier log-rank (ManteleCox) p Z 0.017.treatment after transurethral resection of the bladder
tumor only due to financial constraints or a lack of insur-
ance cover. The underlying cause is not only socioeconomic
problems, but also our patients’ lack of knowledge and
trust of in Western medicine, which explains why most of
our patients prefer herbal or traditional medicines.2
Treatment refusal significantly hinders cancer treatment
in Indonesia and contributes to lower survival rates.
Transurethral resection of the bladder tumor only as a
bladder-sparing treatment for MIBC has been reported
previously. Barnes et al12 reported a 27% 5-year overall
survival in 85 patients with T2 moderate to well-
differentiated bladder tumors who underwent transure-
thral resection of the bladder tumor only. Results from
single-institution studies indicate that transurethral resec-
tion of the bladder tumor only may produce oncological
outcomes equivalent to radical cystectomy. Herr13 reported
a 76% 10-year disease-specific survival in selective patients
who had no residual tumor after repeat transurethral
resection of the bladder tumor.13 However, this protocol
necessitates active surveillance and is limited to highly
selective patients in whom complete tumor resection can
be performed and requires that biopsy samples or repeat
resection of the deep muscle layer in the tumor bed are
negative for the presence of tumors.14 In our centers, the 5-
year overall survival of those who underwent transurethral
resection of the bladder tumor only was only 8.3%, which is
significantly lower than those who were treated with cys-
tectomy or radiotherapy. It was not our intention to
perform, and we do not recommend, transurethral resec-
tion of the bladder tumor only for the primary treatment of
MIBC. This is because survival and the oncological outcomes
are lower than in other treatment modalities. Our patients
also have poor compliance for active surveillance following
transurethral resection of the bladder tumor only.
Radical cystectomy is currently regarded as the main-
stay treatment for MIBC. Meta-analysis of randomized trials
shows that radical cystectomy is superior to radiotherapy,
with 5-year overall survival Peto odds ratios favoring sur-
gery over radiotherapy (odds ratio 1.85, 95% confidence
interval 1.22e2.82).15 A cohort of 1100 patients undergoing
188 W. Supit et al.radical cystectomy without neoadjuvant treatment for
muscle-invasive urothelial carcinoma of the bladder had a
10-year overall survival and disease-specific survival of
44.3% and 66.8%, respectively.16 Cystectomy is the
preferred treatment for muscle-invasive urothelial carci-
noma of the bladder in our centers and our 5-year overall
survival for radical cystectomy without neoadjuvant or
adjuvant chemotherapy was 50% for all patients and 62.5%
for patients with stage T2 disease.
Comparative Asian studies from Taiwan reported a 5-
year overall survival of 53% for all stages and 62% for pa-
tients with stage T2 disease,17 whereas a large cystectomy
series from Japan reported a 5-year overall survival of 58%
for all stages and 67% for patients with stage T2, N0, M0
disease.18 Albeit slightly lower, our survival rates are
comparable with these studies, considering the use of
neoadjuvant or adjuvant chemotherapy in 5.4% and 48.3%
of all the patients in the two earlier studies, respectively.
Meta-analysis of neoadjuvant cisplatin-based chemo-
therapy shows an absolute overall survival benefit of 6.5%
(95% confidence interval 2e11%), from 50% to 56.5% sur-
vival.19 Recent studies suggest that a significant improve-
ment in survival of those treated with adjuvant
chemotherapy is greatest in patients with higher risk dis-
ease with extravesical extension (T3 or more), or patho-
logically proved lymph node (Nþ) metastasis.20
Another reason for our lower survival was our higher
early mortality rate, despite the similar rate of early mor-
bidities compared with other reports. This is mainly due to
our higher number of preoperative comorbidities, more
advanced tumor stage at initial presentation, and lower
hospital volume for this particular procedure.10 Radical
cystectomy performed at higher volume centers is known to
improve postoperative outcomes, including decreased
mortality, a shorter length of stay in hospital, and lower
rates of re-hospitalization.21,22 The time delay to cys-
tectomy is also known to affect survival; treatment delay
beyond 90 days after diagnosis is associated with a worse
survival, but our mean delay time to cystectomy was
shorter than this.23 Although in most other studies delays
were due to neoadjuvant treatment, which is beneficial for
the outcome, the delay in our centers was mostly due to
personal or financial reasons.
Recent interest in quality of life issues has increased
the trend towards bladder preservation modalities for
MIBC. Many centers now apply chemoradiation on an
elective basis for medically fit patients to preserve a
natural functioning bladder with a better quality of
life.5,24 In our centers, radiotherapy was offered initially
to older or morbidly ill patients who were medically unfit
for surgery. However, the potential complications associ-
ated with radical cystectomy along with quality of life is-
sues, such as the cost of stoma bags and frequent
aftercare, discouraged most of our patients, who opted for
radiotherapy despite being informed of the superior
outcome of cystectomy.2
The 5-year overall survival for those receiving radio-
therapy in our centers is 22%. Our result is comparable with
that of older studies in which the 5-year overall survival of
patients receiving radiotherapy only was 22% and 23%,
respectively.25,26 Our current report is in agreement with
other studies which imply that radiation alone as theprimary treatment for MIBC is inferior to cystectomy when
survival is the endpoint. Another Asian study similarly re-
ported the inadequate results of conventional radiotherapy
alone in curing unselected patients or those with poor
prognosis MIBC, particularly those with locally advanced
disease.27
Several arguments against a bladder-sparing approach
include a lower survival rate than radical cystectomy and
fear that the failure of radiotherapy in achieving a com-
plete response may lead to lower survival associated with
salvage cystectomy. Nevertheless, a recent study has
shown that the disease-free rate of patients undergoing
salvage surgery (44% at 10 years) is similar to that observed
in patients treated with radical cystectomy, thus confirming
that salvage treatment is not associated with a worse
overall survival.28
Long-term studies also showed a similar survival
outcome for radical cystectomy compared with radio-
therapy, provided that neoadjuvant or adjuvant chemo-
therapy is added to the regimen.7,28,29 Meta-analysis of
neoadjuvant chemotherapy in advanced bladder cancer
provides evidence of a 5% absolute benefit and 13% relative
risk reduction in death.30 Nevertheless, neoadjuvant or
adjuvant chemotherapy regimens have not become a part
of our standard care due to cost considerations and have
only been occasionally administered in select patients in
recent years.
The limitations of this study include all of those inherent
in a retrospective analysis. Comparing cystectomy with
radiotherapy from retrospective data may not be very ac-
curate. No definite conclusions can be drawn from such an
indirect comparison about which treatment is superior, as it
may be biased by the difference between the pathological
and clinical staging of radical cystectomy versus radio-
therapy, as the latter tends to under-stage the real extent
of a tumor.31
Although all the data elements were prospectively
collected and follow ups were carried out periodically for
each patient visit, there was still a considerable number of
lost patients. The remaining patients who were eligible for
analysis may result in an overestimation or underestimation
of survival. Owing to the limited number of patients, we
were also unable to carry out a subset survival analysis for
each T stage of bladder cancer. The small number of
evaluable patients with T3 disease only allowed a valid
survival analysis of all patients and those with stage T2
disease. We also acknowledge that our limited and unequal
data samples may potentially decrease the statistical
power of this study.
Age and comorbidities are known to influence the choice
of primary treatment in MIBC; those receiving radiotherapy
were significantly older than the patients undergoing cys-
tectomy. In this instance, disease-specific survival would be
a better tool than overall survival for the assessment of
treatment efficacy as it eliminates confounding factors due
to other causes of death. However, from the available data
we could only analyze the overall survival. Further pro-
spective studies should address these limitations by means
of coordinated active surveillance backed by a reliable
death registration system.
In conclusion, this study provides a representative
overview of the treatment outcomes of muscle-invasive
Treatment outcomes for invasive bladder cancer 189urothelial carcinoma results from tertiary cancer centers in
Indonesia. From our series, radical cystectomy yields su-
perior outcomes compared with radiotherapy or transure-
thral resection of the bladder tumor only, a result which is
comparable with those reported elsewhere. Therefore
radical cystectomy with pelvic lymph node dissection and
urinary diversion should be the gold standard treatment for
organ-confined MIBC in Indonesian patients.
In the setting of bladder preservation, transurethral
resection of the bladder tumor only is not a recommended
primary treatment option for muscle-invasive urothelial
carcinoma as the survival rate is very low compared with
other forms of active treatment. Radiotherapy alone also
cannot achieve survival rates equivalent to those achieved
with cystectomy, but comparable outcomes may be ach-
ieved with a trimodal approach combining transurethral
resection of the bladder tumor only, radiotherapy, and
neoadjuvant or adjuvant chemotherapy. Therefore com-
bined chemoradiation is a feasible treatment alternative in
selected and highly compliant patients if cystectomy is not
applicable due to clinical or personal reasons.
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